POINT Biopharma announced the filling of its vacant board seat with the appointment of Bridget Martell, M.A., M.D. to its Board of Directors. Dr. Martell is currently President and CEO of Artizan Biosciences, Inc., a precision medicine drug development platform company focusing on inflammatory disease and the microbiome.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PNT:
- POINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023
- POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO
- POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer
- POINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
- PNT Upcoming Earnings Report: What to Expect?
